Patents Assigned to Cancer Research Campain Technology Ltd.
  • Patent number: 6492116
    Abstract: The present invention concerns a new assay which allows the identification of compounds which inhibit the formation of complexes between a product of the double minute 2 gene (“dm2”) and p53 but not between p53 and DNA. Both the complex formation of labeled DNA, C-terminally truncated p53 and dm2 and disruption of dm2 from the labeled DNA-p53 complex by an inhibitor of the p53-dm2 interaction can be detected by a gel shift assay procedure. This assay permits the selection of compounds which, besides their inhibitory property, do not alter p53 specific DNA binding and do not disturb p53 conformation required for DNA binding or formation of active tetramer.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 10, 2002
    Assignee: Cancer Research Campain Technology Ltd.
    Inventors: Patrick Chène, Heinz-Kurt Hochkeppel